The investigation for the improvement of muscle mass and muscle strength using a branched-chain amino acid (BCAA)-enriched nutrient (Aminoleban EN) in patients with liver cirrhosis associated with liver encephalopathy

The investigation for the improvement of muscle mass and muscle strength using a branched-chain amino acid (BCAA)-enriched nutrient (Aminoleban EN) in patients with liver cirrhosis associated with liver encephalopathy - The investigation of muscle mass and muscle strength using a branched-chain amino acid in patients with decompensated liver cirrhosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018278

Enrollment

100

Registered

2015-07-12

Start date

2015-07-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

decompensated liver cirrhosis

Interventions

A branched-chain amino acid (BCAA)-enriched nutrient (Aminoleban EN) twice daily for 6 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Cirrhotic patients with less than 3.5 g/dl of serum albumin level. 2.Cirrhotic patients with liver encephalopathy 3.Patients who will be able to obtain written informed consent. 4. Age is more 20 years old and less or equal 80 years old, male and female

Exclusion criteria

Exclusion criteria: 1.Patients treated with albumin preparation. 2.Cirrhotic patients with less than 2.5 g/dl of serum albumin level. 3. Cirrhotic patients with more than 3.0 g/dl of serum bilirubin level. 4. Cirrhotic patients with more than third degree liver encephalopathy 5.Patients with history of hypersensitive against drugs. 6.Patients judged to be inappropriate for the study by the investigator.

Design outcomes

Primary

Measure	Time frame
Change of muscle mass and muscle strength after administration of the agent	—

Secondary

Measure	Time frame
1)Change of blood cell count(WBC, RBC, lymphocyte, Plt) 2)Rate of side effect 3)compliance	—

Countries

Japan

Contacts

Public Contactuojima haruki

shonan kamakura general hospital department of gastroenterology

kiruha555@yahoo.co.jp0467-46-1717

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026